Assessment of Hematological Toxicity of Adjuvant Chemotherapy in the Complex Therapy of Breast Cancer.

Abstract

Within the framework of multicenter clinical studies of the original anticancer drug "Arglabin" in the complex therapy of breast cancer (BC) in an increased dose on the basis of the Regional Oncological Dispensary, Karaganda, 80 patients BC were examined and treated: 40 patients in the control group and 40 in the study group. The index of grade I anemia was higher in patients of the control group: in (15.6±6.42)% of patients with polychemotherapy (PCT) AC and in (6.9±4.7)% of patients with PCT according to the scheme AC+Arglabin (p<0.05). The inclusion of Arglabin to the AC regimen increases the rate of absence of toxicity to blood leukocytosis by 25.2% (69.0±8.6%) compared with the group of patients receiving APCT according to the AC regimen (43.8±8.8%); decrease in grade I leukopenia by 2.7 times (from 28.13±7.95% to 10.3±5.7%, p≤0.05); 2-fold decrease in grade 2 leukopenia (from 28.1±7.95% to 13.8±6.4%). The inclusion of Arglabin to the AC regimen in APCT in BC patients increases the rate of absence of toxicity to blood granulocytosis by 14.8% (67.9±8.8%) compared to the group of patients who received APCT according to the AC regimen (53.1±8.8%); a decrease in grade 2 granulocytopenia by 3.9 times (from 28.1±7.95% to 7.14±4.9%, p≤0.05). The inclusion of Arglabin to the adjuvant chemotherapy regimen eliminates the toxic effect of chemotherapy on erythrocytosis, leukocytosis and granulocytosis. No effect of arglabin on blood platelets indicators in breast cancer patients was revealed.